




RealRate

PHARMACEUTICAL 2018

Kiora Pharmaceuticals INC
Rank 289 of 332



The relative strengths and weaknesses of Kiora Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiora Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Kiora Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 127%, being 125% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	8,459
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,834
Liabilities, Non-Current	1,399
Other Assets	5,790
Other Compr. Net Income	7.3
Other Expenses	-1,342
Other Liabilities	0
Other Net Income	-0.65
Other Revenues	408
Property and Equipment	56
Research and Development	10,330
Selling, General and Administrative Expense	4,636

Output Variable	Value in 1000 USD
Assets	14,305
Liabilities	16,232
Expenses	13,625
Revenues	408
Stockholders Equity	-1,927
Net Income	-13,218
Comprehensive Net Income	-13,214
BaseVar	22,289
ECR before Limited Liability	-114%
Economic Capital Ratio	127%